Management of primary antibody deficiency syndromes

Annals of Allergy, Asthma & Immunology

December  2016 Volume 117, Issue 6, Pages 620-626  CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:
Vincent R. Bonagura, MD (Author)
Artemio Miguel Jongco, MPH, MD, PhD (Author)
Blanka Kaplan, MD (Author) 
Jonathan A. Bernstein, MD (CME Subcommittee)
Guha Krishnaswamy, MD (CME Subcommittee)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr., MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Describe strategies to individualize Immunoglobulin G replacement therapy for patients
Discuss non Immunglobulin G adjunct therapies that can be used for managment of immunodeficiency patients

Additional information

V.R. Bonagura has been a consultant for CSL Behring and Baxalta; has received research grants from New York State Department of Health (NYSDOH) and Center for Disease Control (CDC); A.M. Jongco, and B. Kaplan have nothing to disclose; M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, HRSA and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for GlaxoSmithKline, Meda, Mylan, and Teva; has received research grants from AstraZeneca, Bristol-Myers Squibb, Genentech, InterMune, Novartis, and Sunovion. J.A. Bernstein, and G. Krishnaswamy have nothing to disclose. Reviewers and Education/ Editorial staff have no relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.